Ceramide in angiogenic integrin signaling
Ceramide in angiogenic integrin signaling
批准号:
7060518
负责人:
ANAT ERDREICH-EPSTEIN
金额:
$9.59万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-05-01 至 2007-04-30
关键词:
RNA interferenceangiogenesisapoptosisathymic mousebiological signal transductioncell lineceramidesclinical researchenzyme activitygene expressiongenetically modified animalshuman tissueintegrinsmolecular oncologyneoplasm /cancer blood supplyneoplastic growthsmall interfering RNAsphingomyelin phosphodiesterasetransfection /expression vectorvascular endotheliumvitronectin
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Angiogenesis, the sprouting of new capillaries, is essential for cancer growth. Inhibition of integrins av-beta3/av-beta5, cell surface receptors critical in angiogenesis, induces endothelial apoptosis, disrupts angiogenesis and inhibits brain tumor growth in a mouse model. The potential utility of integrin av-beta3/av-beta5 inhibition in cancer therapy is becoming apparent with the encouraging responses to RGDfV, an integrin-function-blocking peptide that completed a phase-I clinical trial in adults with recurrent gliomas. Despite the emerging use of av-beta3/av-beta5 integrin inhibition in cancer therapy, especially against brain tumors, the molecular mechanism of this inhibition is poorly understood, precluding rational design of combination therapies for future trials. We have shown that integrin inhibition increases intracellular ceramide, a pro-apoptotic lipid second messenger. It is not known whether this ceramide increase is required for the anti-angiogenic action of integrin av-beta3/av-beta5 inhibition. Our recent data suggest that acid sphingomyelinase is critical in this mechanism. We hypothesize that the ceramide increase, generated by acid sphingomyelinase and induced by integrin- av-beta3/av-beta5 inhibition is required for endothelial apoptosis and for the effect of RGDfV against brain tumors in vivo. Our Specific Aims are: 1) To determine molecular interactions between ceramide, integrins av-beta3/av-beta5 and apoptosis, and 2) To compare the inhibitory effect of RGDfV in WT and ASMase deficient mice using an intracranial mouse brain tumor model. In vitro we will use ASMase-deficient or -competent endothelial cells plated on vitronectin and compare their ceramide and apoptotic responses to RGDfV. In-vivo we will implant intracranial brain tumors in ASMase knockout mice and wild type littermates and determine differences in survival, tumor growth and angiogenesis in RGDfV- or control-treated mice between the groups. Demonstration of a requirement for acid sphingomyelinase in av-beta3/av-beta5 integrin-mediated endothelial apoptosis will be the first evidence for a causal role of ceramide in integrin signaling. Requirement for ceramide metabolism in integrin signaling has potentially far-reaching implications by providing a molecular rationale for combining integrin-inhibiting drugs with agents geared to optimize the ceramide response, resulting in improved anti-cancer efficacy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of GABA Transaminase ABAT in Pediatric Brain Tumor Medulloblastoma Development and Spread
-
批准号:10716956
-
项目类别:
-
资助金额:$57.96万
-
财政年份:2023
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Summer Oncology Research Fellowship for Medical Students
-
批准号:10260412
-
项目类别:
-
资助金额:$28.08万
-
财政年份:2019
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Summer Oncology Research Fellowship for Medical Students
-
批准号:10453624
-
项目类别:
-
资助金额:$23.46万
-
财政年份:2019
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Summer Oncology Research Fellowship for Medical Students
-
批准号:10672333
-
项目类别:
-
资助金额:$28.39万
-
财政年份:2019
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Stabilizing PID1 to improve medulloblastoma response to cisplatin
-
批准号:9651649
-
项目类别:
-
资助金额:$25.43万
-
财政年份:2018
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Molecular mechanism of PID1, a novel tumor inhibitor, in glioblastomas
-
批准号:9020123
-
项目类别:
-
资助金额:$21.85万
-
财政年份:2015
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Therapy for leptomeningeal medulloblastoma by a novel implantable pump
-
批准号:8840675
-
项目类别:
-
资助金额:$22.93万
-
财政年份:2014
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Tumor-Inhibitory Effects of P1D1 in Gliomas
-
批准号:8329626
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2011
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Tumor-Inhibitory Effects of P1D1 in Gliomas
-
批准号:8227304
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2011
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Ceramide in angiogenic integrin signaling
-
批准号:6861211
-
项目类别:
-
资助金额:$9.82万
-
财政年份:2005
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Brain tumor angiogenesis: Integrin ceramide signaling
-
批准号:6825097
-
项目类别:
-
资助金额:$30.32万
-
财政年份:2004
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Brain tumor angiogenesis: Integrin ceramide signaling
-
批准号:7227715
-
项目类别:
-
资助金额:$26.64万
-
财政年份:2004
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Brain tumor angiogenesis: Integrin ceramide signaling
-
批准号:7104361
-
项目类别:
-
资助金额:$27.44万
-
财政年份:2004
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Brain tumor angiogenesis: Integrin ceramide signaling
-
批准号:6922911
-
项目类别:
-
资助金额:$28.1万
-
财政年份:2004
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
Brain tumor angiogenesis: Integrin ceramide signaling
-
批准号:7429686
-
项目类别:
-
资助金额:$26.64万
-
财政年份:2004
-
负责人:ANAT ERDREICH-EPSTEIN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
-
批准号:82372007
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:谢文晖
-
依托单位:
PROCR信号通路介导的血管新生在卵巢组织移植中的作用及机制研究
-
批准号:82371726
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:李文
-
依托单位:
RNA编辑型IGFBP7在肿瘤细胞与肿瘤血管微环境中的调控作用及机制研究
-
批准号:32070790
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:徐小燕
-
依托单位:
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
-
批准号:81200692
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2012
-
负责人:陈凌
-
依托单位:
基于新生血管显像研究MSC治疗缺血性脑血管病的转化医学关键问题
-
批准号:81171370
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:朱朝晖
-
依托单位:
探索VASH2转录激活对肝细胞癌血管生成和上皮间质转化的作用及机制
-
批准号:81172267
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:高文涛
-
依托单位:
解析miR-566调控VHL/β-catenin信号通路影响人脑胶质瘤血管新生的分子机制
-
批准号:81101916
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:周旋
-
依托单位:
脂肪组织来源干细胞促进颗粒脂肪游离移植后再血管化机制的实验研究
-
批准号:81171834
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:鲁峰
-
依托单位:
99mTc-3PRGD2 SPECT显像用于评价肺癌抗新生血管药物疗效的动物研究及肺癌诊断临床研究
-
批准号:81171369
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2011
-
负责人:李方
-
依托单位:
核素靶向示踪肿瘤新生血管作用位点研究
-
批准号:81071183
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:王荣福
-
依托单位: